Automatic Holter electrocardiogram analysis in ischaemic stroke patients to detect paroxysmal atrial fibrillation: ready to replace physicians?

BACKGROUND AND PURPOSE: The detection of paroxysmal atrial fibrillation (pAF) in patients presenting with ischaemic stroke shifts secondary stroke prevention to oral anticoagulation. In order to deal with the time- and resource-consuming manual analysis of prolonged electrocardiogram (ECG)-monitoring data, we investigated the effectiveness of pAF detection with an automated algorithm (AA) in comparison to a manual analysis with software support within the IDEAS study [study analysis (SA)]. METHODS: We used the dataset of the prospective IDEAS cohort of patients with acute ischaemic stroke/transient ischaemic attack presenting in sinus rhythm undergoing prolonged 72-h Holter ECG with central adjudication of atrial fibrillation (AF). This adjudicated diagnosis of AF was compared with a commercially available AA. Discordant results with respect to the diagnosis of pAF were resolved by an additional cardiological reference confirmation. RESULTS: Paroxysmal AF was finally diagnosed in 62 patients (5.9%) in the cohort (n = 1043). AA more often diagnosed pAF (n = 60, 5.8%) as compared with SA (n = 47, 4.5%). Due to a high sensitivity (96.8%) and negative predictive value (99.8%), AA was able to identify patients without pAF, whereas abnormal findings in AA required manual review (specificity 96%; positive predictive value 60.6%). SA exhibited a lower sensitivity (75.8%) and negative predictive value (98.5%), and showed a specificity and positive predictive value of 100%. Agreement between the two methods classified by kappa coefficient was moderate (0.591). CONCLUSION: Automated determination of 'absence of pAF' could be used to reduce the manual review workload associated with review of prolonged Holter ECG recordings.

[Catheter ablation of ventricular tachycardia : What have we achieved?] / Katheterablation ventrikulärer Tachyarrhythmien : Was haben wir erreicht?

The role of catheter ablation in patients with ventricular tachycardia (VT) has evolved over the last two decades into an established treatment option. In patients with idiopathic VT catheter ablation is the gold standard treatment option with high effectiveness and low risk of complications. Due to the high risk of side effects the use of antiarrhythmic drugs is only indicated in exceptional cases. In patients with structural heart diseases, such as ischemic and dilated cardiomyopathy, VT is the most frequent cause of death. Furthermore, recurrent shocks from implantable cardioverter defibrillators (ICD) are one of the main reasons for the high morbidity and mortality; however, in these patients a complex myocardial substrate is present and consequently there is a relevant risk of recurrence after VT ablation. A periprocedural mortality of approximately 3% must be considered in these often severely ill patients. Nevertheless, there is no reasonable alternative to catheter ablation, particularly in patients who continue to have VT episodes even under therapy with amiodarone. Questions with respect to the optimal procedural technique for VT ablation, the endpoint and optimal timing of ablation need to be clarified in clinical trials.

[Recurrent failed ICD therapy of ventricular tachycardia]. / Wiederholt ausbleibende ICD-Therapie einer ventrikulären Tachykardie.

Implantable cardioverter defibrillators (ICD) are used as standard therapy to prevent sudden cardiac death in heart failure patients. Today, physicians in emergency and intensive care medicine are often confronted with problems of ICD therapy in these patients. We report a case of a patient suffering from recurrent ventricular tachycardia (VT) requiring antiarrhythmia treatment with amiodarone. With an increasing drug loading, the VT cycle length was progressively prolonged resulting in a slow VT undetectable for the ICD. Subsequently, the patient was scheduled for VT ablation after which the patient became free of arrhythmia recurrences.

[Catheter ablation for atrial fibrillation: clinically established or still an experimental method].

Interventional treatment for atrial fibrillation has been introduced as a therapeutic option since the pulmonary veins (PV) have been discovered as the dominant sources of paroxysmal atrial fibrillation (PAF). Elimination of PV conduction is the initial goal during catheter ablation in this setting. The success rate after the initial procedure varies between 60 and 85 %, with more than 80 % after subsequent interventions. Supported by the current guidelines, interventional treatment of AF is indicated in case of symptomatic arrhythmias refractory to antiarrhythmic treatment. The introduction of the combined, stepwise approach has been another important breakthrough with regard to the treatment of chronic persistent atrial fibrillation (CAF). This strategy includes the combination of all conventional ablation strategies (PV isolation, ablation of complex fractionated atrial electrograms, linear ablation) with the goal of AF termination. The first procedure for CAF treatment is quite frequently also only the first step towards stable sinus rhythm with a favourable outcome after AF termination (> 80 % sinus rhythm). In more than half of the patients predominantly other atrial arrhythmias than AF have to be targeted in a second procedure. This approach is currently under clinical investigation and so far not "clinically established" due to the fact that it is a quite time consuming and challenging procedure even in experienced centres. Future studies may help to identify predictors for procedure failure (e.g. LA size, AF duration, atrial cycle length, spectral analysis) in order to improve patient selection. Additionally, it has to be underscored, that in paroxysmal atrial fibrillation the relatively high recurrence rate after the first procedure still is the subject of further investigations. This aspect might be improved by the introduction of novel strategies (i.e. testing of concealed PV conduction after ablation with adenosine) or new technologies (i.e. robotic navigation) for PAF ablation.

Quantification of mechanical ventricular dyssynchrony: direct comparison of velocity-encoded and cine magnetic resonance imaging.

PURPOSE: The preoperative assessment of mechanical dyssynchrony can help to improve patient selection in candidates for cardiac resynchronization therapy (CRT). The present study compared the performance of velocity-encoded (VENC) MRI to cine-magnetic resonance imaging (MRI) for quantifying mechanical ventricular dyssynchrony. MATERIALS AND METHODS: VENC-MRI and cine-MRI were performed in 20 patients with heart failure NYHA class III and reduced ejection fraction (median: 24 %, interquartile range: 18 - 28 %) before CRT device implantation. The interventricular mechanical delay (IVMD) was assessed by VENC-MRI as the temporal difference between the onset of aortic and pulmonary flow. Intraventricular dyssynchrony was quantified by cine-MRI, using the standard deviation of time to maximal wall thickening in sixteen left ventricular segments (SDt-16). The response to CRT was assessed in a six-month follow-up. RESULTS: 14 patients (70 %) clinically responded to CRT. A similar accuracy was found to predict the response to CRT by measurements of the IVMD and SDt-16 (75 vs. 70 %; p = ns). The time needed for data analysis was significantly shorter for the IVMD at 1.69 min (interquartile range: 1.66 - 1.88 min) compared to 9.63 min (interquartile range: 8.92 - 11.63 min) for the SDt-16 (p < 0.0001). CONCLUSION: Measurements of the IVMD by VENC-MRI and the SDt-16 by cine-MRI provide a similar accuracy to identify clinical responders to CRT. However, data analysis of the IVMD is significantly less time-consuming compared to data analysis of the SDt-16.

[Interventional therapy of atrial fibrillation: possibilities and limitations]. / Möglichkeiten und Grenzen der interventionellen Therapie von Vorhofflimmern.

Recently, significant progress has been made treating atrial fibrillation (AF) with catheter ablation emerging as an increasingly important technique. Electrical disconnection of the pulmonary veins (PV) is a widely accepted endpoint for interventional treatment of paroxysmal AF (PAF). According to the current guidelines, catheter ablation can be considered as a therapeutic option in patients who failed antiarrhythmic drug treatment for PAF. The procedural endpoint for PVI is achievement of permanent electrical isolation of the PVs, which in the vast majority of patients harbor triggered electrical activity inducing and maintaining PAF. The success rate of this approach in patients with PAF ranges between 60 and 80% after a single procedure and augments to > 80 % in patients undergoing a repeat procedure to abolish recovered PV connection. However, it is now evident that persistent or long-standing persistent AF may not be successfully treated by PVI alone since the majority of patients have AF maintaining substrate beyond the PV. From a pathophysiological perspective this is explained by structural and electrical remodeling of the atrial myocardium in patients with persistent AF. Therefore, it is today widely accepted that additional substrate modification is required to effectively address persistent AF using catheter ablation. It has been shown that a combined approach of PV isolation, ablation of fractionated atrial electrograms and application of lines to treat atrial macro-reentrant tachycardias ("stepwise approach") aiming for restoration of sinus rhythm is a favorable strategy to treat persistent AF. However, significant expertise is needed to accomplish all steps within these complex procedures. Therefore, catheter ablation for persistent AF cannot yet be considered "clinically established" and should only be performed in high volume centers. Additional data is needed to verify the beneficial effect of this strategy and determine "predictors" identifying patients profiting most from these ablation strategies. In patients with PAF, catheter ablation has emerged as an established therapy also in comparison to antiarrythmic drug treatment. Recent studies have shown that catheter ablation for PAF is superior to antiarrhythmic drug treatment with regard to mid-term suppression of any atrial arrhythmia. Overall, catheter ablation for AF has still to be considered as a symptomatic treatment since evidence for beneficial effects with regard to more robust clinical endpoints such as death, rehospitalization and ischemic cerebral events are not yet available.

[Surface ECG presentation and intracardiac electrogram characteristics of uncommon supraventricular tachycardia entities]. / Differenzialdiagnose ungewöhnlicher Elektrogramme - vom Oberflächen-EKG zur elektrophysiologischen Diagnose.

The vast majority of patients with supraventricular tachycardias present with specific 12-lead surface ECG characteristics allowing the diagnosis of the underlying mechanisms prior to the invasive electrophysiological study. However, an accurate diagnosis remains challenging in a subset of patients, even when using well-established stimulation maneuvers and sophisticated conventional mapping methods. Thus, the aim of the present manuscript is to describe some cases with uncommon entities of supraventricular tachycardias where the combined interpretation of 12-lead ECG presentation and invasive electrophysiological characteristics revealed the correct diagnoses.

[Modern pharmacotherapy of supraventricular and ventricular cardiac arrhythmia. An update for conventional therapy]. / Moderne Pharmakotherapie bei supraventrikulären und ventrikulären Herzrhythmusstörungen. Ein Update zur konventionellen Therapie.

Currently the pharmacological approach still represents the mainstay in the acute phase of arrhythmia management as well as in the chronic treatment phase of specific entities such as atrial fibrillation. However, non-pharmacological options have recently emerged as frequently used first-line tools for the treatment of various supraventricular and ventricular heart rhythm disturbances. Nevertheless, antiarrhythmic drug treatment is frequently used as a bridging or adjunctive therapy in conjunction with catheter ablation or implantable cardioverter defibrillators. Antiarrhythmic agents constitute a very heterogeneous group prone to various drug interactions and side-effects. Therefore, this article aims to summarise the most important facts and recent findings with regard to appropriate contemporary pharmacological therapy of atrial and ventricular arrhythmias in clinical practice.

Echocardiographic advances in atrial fibrillation and supraventricular arrhythmias.

Advances in echocardiography have paved the way for the development of intracardiac catheters with ultrasound transducers mounted on its tip. With this technology it has become possible for the interventional electrophysiologist to perform continuous echocardiographic examination during a procedure without the need for general anaesthesia or additional staff. Intracardiac echocardiography (ICE) allows the monitoring of catheter movement in real-time, assessment of catheter-tissue contact and potentially prevents and recognizes complications like thrombus formation and pericardial effusion. In addition recent technologies allow acquiring the full spectrum of Doppler-imaging permitting evaluation of haemodynamic data during the procedure. All these advances have made ICE an ideal tool for the interventional electrophysiologist, serving as a diagnostic and imaging tool during invasive electrophysiological procedures. This review will summarize currently available technology of ICE and its indications and applications in electrophysiological procedures.

Radiofrequency catheter ablation of two accessory pathways with different unidirectional conduction properties.

Simultaneous occurrence of narrow and broad QRS complex tachycardias in patients with WPW syndrome usually indicates a macroreentry in an orthodromic atrioventricular reentry-tachycardia using the AV node as antegrade and the accessory pathway as retrograde conduction and vice versa in an antidromic circuit. We report on a 32-year-old woman with WPW syndrome presenting with both a narrow and a broad QRS complex tachycardia using two accessory pathways with different unidirectional conduction properties in combination of an exclusively antegrade conducting AV node. This case report describes conventional mapping techniques and ablation of this unusual entity of a WPW syndrome.